Candriam SCA’s Forma Therapeutics Holdings, Inc. Common Stock FMTX Stock Holding History

Candriam SCA’s Portfolio FMTX Stock Details FMTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-54,112	Closed	-$1.08M	–	910
2022 Q3	$1.08M	Sell	54,112 -238,580	-82%	-$3.15M	0.01%	693
2022 Q2	$2.02M	Hold	292,692	–	–	0.02%	506
2022 Q1	$2.72M	Hold	292,692	–	–	0.02%	479
2021 Q4	$4.16M	Hold	292,692	–	–	0.03%	390
2021 Q3	$6.79M	Hold	292,692	–	–	0.05%	334
2021 Q2	$7.29M	Buy	292,692 +169,688	+138%	+$4.56M	0.05%	332
2021 Q1	$4.12M	Hold	123,004	–	–	0.03%	404
2020 Q4	$4.29M	Sell	123,004 -119,578	-49%	-$5.21M	0.03%	415
2020 Q3	$12.1M	Buy	+242,582	New	+$9.8M	0.11%	198

Candriam SCA's FMTX Position: Q4 2022 in Review

Candriam SCA sold out of Forma Therapeutics Holdings, Inc. Common Stock (FMTX) in Q4 2022, closing a stake of 54,112 shares — an estimated $1.08M sold.

Candriam SCA first reported a position in FMTX in Q3 2020 and held it in 9 quarters. The position peaked at $12.1M in Q3 2020. 0 funds tracked by Wall St. Rank hold FMTX as of Q4 2022.

Candriam SCA reported no remaining Forma Therapeutics Holdings, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Candriam SCA sold 54,112 Forma Therapeutics Holdings, Inc. Common Stock shares in Q4 2022, an estimated $1.08M.
Candriam SCA first reported a position in Forma Therapeutics Holdings, Inc. Common Stock in Q3 2020 and held it in 9 quarters.
Candriam SCA's Forma Therapeutics Holdings, Inc. Common Stock position peaked at $12.1M in Q3 2020.
0 funds tracked by Wall St. Rank held Forma Therapeutics Holdings, Inc. Common Stock as of Q4 2022.

Based on Candriam SCA's 13F filing for Q4 2022, filed 13 Feb 2023.